NCT06038994

Brief Summary

To evaluate the prognostic value of surem TRAF3IP2 levels in patients with acute myocardial infarction

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2023

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

September 7, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 15, 2023

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

September 15, 2023

Status Verified

September 1, 2023

Enrollment Period

8 months

First QC Date

September 7, 2023

Last Update Submit

September 8, 2023

Conditions

Myocardial Infarction, Acute

Keywords

TRAF3IP2, Myocardial Infarction, Coronary angiography, MACEs

Outcome Measures

Primary Outcomes (1)

  • MACEs (major adverse cardiac events)

    MACEs were defined as a composite of cardiac death, hospitalization for myocardial infarction or heart failure

    1 year

Secondary Outcomes (2)

  • cardiac death

    1 year

  • hospitalization for myocardial infarction or heart failure

    1 year

Study Arms (1)

Patients with acute myocardial infarction who experienced CAG

Patients with acute myocardial infarction who experienced coronary angiography

Other: No intervention

Interventions

No interventionOTHER

This is an obvertional study, and there is no intervention.

Patients with acute myocardial infarction who experienced CAG

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with acute myocardial infarction who received coronary angiography well enrolled in Huai'an First People's Hospital

You may qualify if:

  • Patients with acute myocardial infarction
  • patients received coronary angiography
  • invasive management within 72 h of hospital admission

You may not qualify if:

  • NYHA III-IV
  • malignant tumor
  • acute infection
  • thyroid dysfunction
  • Life expectancy of b1 y
  • Unsuitable for PCI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Huai'an First People's Hospital

Huai'an, Jiangsu, 223300, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

The blood sample will be collected, and the surem TRAF3IP2 levels will be measured using ELASA.

MeSH Terms

Conditions

Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Officials

  • Shuren Ma, MD.

    NJMU

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jin Geng, MD.

CONTACT

+86-17753124846gj885258@163.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate doctor

Study Record Dates

First Submitted

September 7, 2023

First Posted

September 15, 2023

Study Start

September 1, 2023

Primary Completion

April 30, 2024

Study Completion

April 30, 2025

Last Updated

September 15, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

There is not a plan to make IPD available.

Locations

CN(1)